TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Rivaroxaban 2.5 mg BID and Aspirin for Intermittent Claudication in PAD Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with symptomatic PAD who signed the informed consent form (ICF) with:~  1. Ankle-brachial index (ABI) \< 0. 85 in at least one member, and~ 2. ACD \< 500 meters~ 3. age \> 18 years~ 4. No history of lower-limbs arterial bypass surgery or angioplasties in the last year~ 5. walking ability limited by the symptom of claudication and~ 6. ability to complete a treadmill test~Exclusion Criteria:~1. high risk of bleeding~   - Evidence of a recent history of bleeding in the last three months, hemorrhagic diathesis in the last three months, changes in coagulation tests (INR\> 1.5 or aPTT \> 2), pulmonary bronchiectasis, active cancer, active gastroduodenal ulcer, use of dual antiplatelet therapy.~2. Recent hemorrhagic stroke (1 month) or any history of previous hemorrhagic or lacunar stroke, if detected by occasional prior tomography, which is not part of the study protocol.~3. severe heart failure (NYHA class III and VI)~4. advanced stable kidney disease (estimated creatinine clearance \<15 ml per minute), defined as eTFG \<15 mL/min by 1.73 m2 calculated by the abbreviated formula Diet Modification in Kidney Disease (MDRD).~5. the use of dual antiplatelet therapy, anticoagulation, or other antithrombotic therapy~6. Continuous use of pentoxifylline or cilostazol~7. Cardiac conditions that may lead to heart failure, such as unstable angina, arrhythmias, acute myocardial infarction in the last three months~8. Non-cardiac conditions that may interfere with the ability to complete functional tests (e.g., chronic obstructive pulmonary disease, anemia, rheumatologic diseases)~9. Non-cardiovascular conditions are considered by the researcher as associated with a poor prognosis.~a. Active cancer with a life expectancy of fewer than six months b. Collagen limiting diseases c. Previous or scheduled surgeries that prevent functional evaluation d. Orthopedic diseases that hinder functional evaluation (j) Pregnancy. Women with the potential to bear children should be under contraceptive strategies and take a negative pregnancy test to be enrolled.~(k) Patients with COVID in the contagious phase (PCR+)~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Vascular dose (Type: EXPERIMENTAL): Rivaroxaban 2.5 mg BID and aspirin 100 mg OD for 6 months
- Aspirin (Type: ACTIVE_COMPARATOR): Aspirin 100 mg OD for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial to Evaluate the Efficacy and Safety of CKD-495

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or Female subjects aged ≥ 19~2. Acute or Chronic gastritis patients who have more than 1 erosion on endoscopy within 7days prior to the use of the Investigator's Product taken date~3. Patients who have more than 1 subjective symptom~Exclusion Criteria:~1. Patients with peptic ulcer, gastroesophageal reflux disease, malignant tumor in the digestive system or coagulation disorder, or taking antithrombotic medicine~2. Patients who have been taken any gastritis medicine that could affect the treatment: H2 receptor antagonist, PPI(Proton Pump Inhibitor), antacid, improvement of movement in digestive system, Prostaglandin, and protective agent for gastritis~3. Patients who have to take medicine that could cause gastritis

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental Group (Type: EXPERIMENTAL): Patients assigned to this group are treated with one CKD-495 75mg Tab.,and one Placebo Tab.(Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab)
- Active comparator Group (Type: ACTIVE_COMPARATOR): Patients assigned to this group are treated with one Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg Tab, and one Placebo Tab.(Placebo of the CKD-495 75mg)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Safety Study of SGN-CD33A in AML Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Acute myeloid leukemia, positive for CD33~* Eastern Cooperative Oncology Group status of 0 or 1~* Adequate baseline renal and hepatic function~* Central venous access~* Either achieved complete remission (greater than 12 weeks in duration) with initial induction/consolidation and have experienced relapse of disease or declined treatment with high-dose induction/consolidation~* Bone marrow blasts greater than or equal to 5% for relapsed patients, or greater than or equal to 20% for untreated patients~Exclusion Criteria:~* Inadequate lung function~* Prior allogeneic stem cell transplant, except for a specific cohort~* High-dose chemotherapy within 4 weeks of study drug~* Antileukemia treatment within 14 days of study drug (other than hydroxyurea or 6-mercaptopurine)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SGN-CD33A + HMA (Type: EXPERIMENTAL): SGN-CD33A with hypomethylating agent
- SGN-CD33A Monotherapy (Type: EXPERIMENTAL): SGN-CD33A

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of PF-05212384 (Also Known as PKI-587)Administered Intravenously To Subjects With Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologic diagnosis of any solid tumor~* Incurable cancer, with disease progression following at least 1 therapy with no further standard treatment available in the opinion of the investigator.~* At least 1 evaluable lesion per RECIST criteria~Exclusion Criteria:~* Clinically unstable primary or metastatic CNS tumors~* Subjects with known diabetes~* QTc interval greater than 470 ms.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): PF-05212384 (also known as PKI-587)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Citalopram Versus Citalopram Plus Pindolol in Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a depressive episode~* HDRS score \> 18~* Written informed consent~Exclusion Criteria:~* suicidal risk \> 3~* severe organic illness~* other psychotropic drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Citalopram + placebo (Type: PLACEBO_COMPARATOR): Citalopram 20 mg/day t.i.d
- Citalopram + pindolol (Type: EXPERIMENTAL): Citalopram 20 mg/day t.i.d Pindolol 15 mg/day t.i.d.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Macrolide Antibiotics on Airway Inflammation in People With Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participating in the COPD Network Macrolide study~* Clinical diagnosis of at least moderate COPD~* Cigarette consumption of 10 pack years or more~Exclusion Criteria:~* Diagnosis of asthma~* Predicted life expectancy of less than 3 years~* History of hypersensitivity to macrolide antibiotics~* Long-term kidney insufficiency~* Long-term liver insufficiency~* Prolonged QT interval~* Use of medications that may prolong the QT interval

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Azithromycin-treated (Type: None): Participants in the COPD Network Macrolide Study who received azithromycin for 1 year.
- Placebo-treated (Type: None): Participants in the COPD Network Macrolide Study who received placebo for 1 year.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Safety Study of MP-513 in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who has been receiving a stable dose and regimen of oral antihyperglycaemic agent (biguanide agent,α-glucosidase inhibitor,rapid insulin secretagogue) for diabetes over 12 weeks before administration of investigational drug~* Patients who are under dietary management and taking therapeutic exercise for diabetes over 12 weeks before administration of investigational drug~* Patients whose HbA1c is between 6.5% - 10.0%~* Patients who were not administered diabetes therapeutic drugs prohibited for concomitant use within 12 weeks before administration of investigational drug~Exclusion Criteria:~* Patients with type 1 diabetes, diabetes mellitus caused by pancreas impairment, or secondary diabetes (Cushing disease, acromegaly, etc)~* Patients who are accepting treatments of arrhythmias~* Patients with serious diabetic complications~* Patients who are habitual excessive alcohol consumption.~* Patients with severe hepatic disorder or severe renal disorder.~* Patients who are pregnant, lactating, and probably pregnant patients, and patients who can not agree to contraception

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- teneligliptin (Type: EXPERIMENTAL): teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained )
- teneligliptin and glinide (Type: EXPERIMENTAL): teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus glinide
- teneligliptin and biguanide (Type: EXPERIMENTAL): teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus biguanide
- teneligliptin and alpha-glucosidase inhibitor (Type: EXPERIMENTAL): teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus alpha-glucosidase inhibitor

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Dose Titration Study of Fentanyl Buccal Soluble Film for Breakthrough Cancer Pain in Taiwan

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* a. a stable current regimen of oral opioids equivalent to 60-1000 mg/day of oral morphine or 20-120 mg/day of iv morphine or 25-300 mcg/hr of transdermal fentanyl for one week or longer;~* b. regularly experienced 1 to 3 breakthrough pain episodes per day that required additional opioids from pain control;~* c. at least partial relief of breakthrough pain by use of opioid therapy;~* d. 20 years of age or older;~* e. ability to understand and willingness to sign a written informed consent document;~* f. able to self-administer the study medication correctly or has the availability of a responsible adult caregiver available to administer the study medication correctly;~* g. willing and able to complete patient diary with each pain episode~Exclusion Criteria:~* a. rapidly escalating pain (e.g., regularly more than 3 breakthrough pain episodes per day) that are hard to be controlled by analgesics;~* b. history of hypersensitivity or intolerance to fentanyl;~* c. cardiopulmonary disease that, in the opinion of the investigator, would significantly increase the risk of respiratory depression;~* d. psychiatric/cognitive or neurological impairment that would limit the subject's ability to understand or complete the diary;~* e. moderate (Grade 3) to severe (Grade 4) mucositis (subjects with less than moderate mucositis are permitted and must be instructed to not apply the Painkyl® film at a site of inflammation);~* f. abnormal oral mucosa which will impede drug absorption;~* g. currently under other treatments that may alter effect of pain control based on investigator's judgment;~* h. recent history or current evidence of alcohol or other drug substance (licit or illicit) abuse;~* i. use of an investigational drug within 4 weeks preceding this study;~* j. pregnant women or nursing mothers, or positive pregnancy test for women of childbearing potential;

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fentanyl buccal soluble film (FBSF) (Type: EXPERIMENTAL): Single arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female adults ≥18 and \<50 years of age.~2. Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.~3. Female subject of childbearing potential or male subject who is able to father children, and willing to use a highly effective method of contraception as outlined in this protocol for at least 28 days after the dose of investigational product; or female subject not of childbearing potential or male subject not able to father children.~Exclusion Criteria:~1. Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.~2. Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.~3. History of microbiologically proven invasive disease caused by S pneumoniae.~4. Pregnant female subjects or breastfeeding female subjects (known or suspected).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- 20vPnC Lot 1 (Type: EXPERIMENTAL): 20vPnC Lot 1
- 20vPnC Lot 2 (Type: EXPERIMENTAL): 20vPnC Lot 2
- 20vPnC Lot 3 (Type: EXPERIMENTAL): 20vPnC Lot 3
- 13vPnC (Type: ACTIVE_COMPARATOR): 13vPnC

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~1. Female patients \>=18 years with proven diagnosis of HER2-overexpressing, histologically confirmed breast cancer~2. Stage IV metastatic disease~3. At least one measurable lesion according to RECIST 1.1 (Response Evaluation Criteria for Solid Tumours version 1.1). Skin, bone and brain lesions are considered non-target lesions~4. Must have failed or progressed on either trastuzumab or lapatinib or trastuzumab and lapatinib treatment in the neoadjuvant and/or adjuvant setting~Exclusion criteria:~1. Prior first line therapy for metastatic breast cancer~2. Known pre-existing interstitial lung disease~3. Active brain metastases~4. History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure NYHA classification of 3, unstable angina or poorly controlled arrhythmia. Myocardial infarction within 6 months prior to trial treatment.~5. Cardiac left ventricular function with resting ejection fraction of less than 50%.~6. Prior treatment with Epidermal Growth Factor Receptor (EGFR)/HER2-targeted small molecules or antibodies other than trastuzumab and lapatinib in the neoadjuvant or adjuvant setting~7. Prior treatment with paclitaxel in the past 12 months~8. Must not have received prior vinorelbine treatment - Further exclusion criteria apply

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Afatinib 40mg once daily (OD) (Type: EXPERIMENTAL): Patient to receive afatinib monotherapy at a dose of 40 mg/d until progression of their disease
- Paclitaxel 80 mg/m2 weekly (Type: EXPERIMENTAL): Patients to additionally receive paclitaxel at a dose of 80 mg/m2 weekly on disease progression on afatinib monotherapy
- Vinorelbine 25 mg/m2 weekly (Type: EXPERIMENTAL): Patients to additionally receive vinorelbine at a dose of 25 mg/m2 weekly on disease progression on afatinib monotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Control Trial to Assess Postoperative Pain After Sling Placement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Any female patient, age 18 or older, who elects to have a mid-urethral sling with or without an anterior or posterior repair at the University of North Carolina Hospitals by a member of the Division of Urogynecology.~Exclusion Criteria:~* Any patient with a chronic pain syndrome, a contraindication to nonsteroidal anti-inflammatory drugs (NSAIDs) such as liver disease, abnormal coagulation, esophageal disorders or peptic ulcers or where pain evaluation is unreliable because of neurological disease and those on treatment with steroids/NSAIDs/opioids prior to surgery.~* Also excluded will be any patient who is having any other reconstructive pelvic surgery concomitantly or would require the placement of a suprapubic catheter.~* Patients electing to have their surgery with regional anesthesia, such as an epidural or spinal will be excluded.~* All minors, decisional impaired people, nursing mothers and non-English speaking people will be excluded.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Patients randomized to this arm will receive 60 cc of 0.125% Marcaine injected into the retropubic space along the tract that the suprapubic mid-urethral trocar will follow (one on each side) for a total of 120 cc of 0.125% Marcaine, prior to the placement of the mid-urethral sling via the suprapubic approach.
- 2 (Type: NO_INTERVENTION): Patients assigned to this arm will have the mid-urethral sling placed via the suprapubic approach in the standard fashion with no injection of Marcaine into the retropubic space.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vardenafil Orodispersible Tablet (ODT) Versus Placebo in Males With Erectile Dysfunction, 50% of Whom Are to be 65 Years or Older.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males 18 years-of-age or older.~* Stable, heterosexual relationship for at least 6 months.~* A history of erectile dysfunction (ED) for at least 6 months~Exclusion Criteria:~* Any underlying cardiovascular condition, including unstable angina pectoris~* History of myocardial infarction, stroke or life-threatening arrhythmia within 6 months prior to visit 1~* Uncontrolled atrial fibrillation / flutter at screening~* History of congenital QT prolongation~* History of surgical prostatectomy due to prostate cancer~* Hereditary degenerative retinal disorders~* History of loss of vision because of NAION (Non-arteritic anterior ischemic optic neuropathy), temporary or permanent loss of vision~* Presence of penile anatomical abnormalities~* Spinal cord injury~* Resting or postural hypotension or hypertension~* Subjects who are taking nitrates or nitric oxide donors, androgens, anti-androgens, alpha-blockers, HIV (Human immunodeficiency virus) protease inhibitors, itraconazole or ketoconazole, and clarithromycin and erythromycin.~* Subjects taking medication known to prolong QT interval, such as Type Ia and Type 3 anti-arrhythmics.~* Subjects who have been confirmed with phenylketonuria (PKU).~* Use of any treatment for ED within 7 days of Visit 1.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vardenafil ODT (STAXYN, BAY38-9456) (Type: EXPERIMENTAL): Vardenafil 10 mg orodispersible tablet (ODT) taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo tablet taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete